Effect of a Plant-Based Nutraceutical Powder on Inflammatory and Oxidative Stress Markers in Rheumatoid Arthritis Patients in Ghana

A Cluster Randomized Controlled Trial Evaluating the Effect of a Standardized Vernonia amygdalina and Synsepalum dulcificum Formulation on Inflammatory Biomarkers, Oxidative Stress, and Clinical Outcomes in Rheumatoid Arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202605866703239

Enrollment

Registered

2026-05-07

Start date

2026-05-04

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Diseases

Interventions

Standard care

Plant based nutraceutical powder

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults =18 years Diagnosed RA (clinical criteria) Stable treatment =3 months Able to consent

Exclusion criteria

Exclusion criteria: • Severe organ disease • Pregnancy/lactation Allergy to plant products Patient below 18 years Current supplement use affecting outcomes Participation in another trial

Design outcomes

Primary

Measure	Time frame
(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)	—

Secondary

Measure	Time frame
secondary outcomes (Disease Activity Score in 28 joints (DAS28), pain assessed using the Visual Analogue Scale (VAS), Health Assessment Questionnaire Disability Index (HAQ-DI), haematological indices, and fasting blood glucose (FBG)). Fasting blood glucose will be measured bsecondary outcomes (Disease Activity Score in 28 joints (DAS28), pain assessed using the Visual Analogue Scale (VAS), Health Assessment Questionnaire Disability Index (HAQ-DI), haematological indices, and fasting blood glucose (FBG)). Fasting blood glucose will be measured.	—

Measure

Time frame

secondary outcomes (Disease Activity Score in 28 joints (DAS28), pain assessed using the Visual Analogue Scale (VAS), Health Assessment Questionnaire Disability Index (HAQ-DI), haematological indices, and fasting blood glucose (FBG)). Fasting blood glucose will be measured bsecondary outcomes (Disease Activity Score in 28 joints (DAS28), pain assessed using the Visual Analogue Scale (VAS), Health Assessment Questionnaire Disability Index (HAQ-DI), haematological indices, and fasting blood glucose (FBG)). Fasting blood glucose will be measured.

—

Countries

Ghana

Contacts

Public ContactFlorence Brenyah

Senior lecturer AAMUTED

brenyaflorence647@gmail.com+2330204213136

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026